Key result
Transcatheter double valve-in-valve replacement treats severe mitral and aortic bioprosthetic stenosis in a case report.
Why the study?
Experience with transcatheter mitral valve replacement remains early due to development challenges and risks such as displacement and LVOT obstruction.
Case Report (n=1)
Describes a case of transcatheter double valve-in-valve replacement for severe mitral and aortic bioprosthetic valve stenosis, highlighting an emerging structural intervention.
TDVIVR may be feasible in select dual bioprosthetic stenosis; leaves open need for prospective safety and durability data.
Transcatheter aortic valve replacement (TAVR) is an evolving method which has become the treatment of choice in high-risk patients with severe aortic stenosis. Unlike TAVR, the experience with transcatheter mitral valve replacement (TMVR) remains at an early stage because of challenges of valve development and possible complications such as valve displacement and subsequent left ventricular outlet tract (LVOT) obstruction. Here we report a case of transcatheter double valve-in-valve replacement (TDVIVR) in a patient with severe mitral and aortic bioprosthetic valve stenosis, followed by an extensive literature review of the latest techniques and challenges in this field.
No takes yet. Share an insight, caveat, or question.
Savoj et al. (2019) conducted a case report in Severe mitral and aortic bioprosthetic valve stenosis (n=1). Transcatheter double valve-in-valve replacement (TDVIVR) was evaluated. Transcatheter double valve-in-valve replacement (TDVIVR) was described in a patient with severe mitral and aortic bioprosthetic valve stenosis, accompanied by a literature review.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: